Xiao, Shuke https://orcid.org/0000-0003-2103-128X
Wang, Mengjie
Martin, Thomas G.
Scott, Barry https://orcid.org/0000-0002-8841-3525
Fang, Xing
Liu, Xinming
Yang, Yongjie
Fu, Sipei
Truong, Steven D.
Gugel, Jack F.
Maas, Gregory L.
Mullen, Marcus P.
Hill, Jennifer Hampton
Li, Veronica L. https://orcid.org/0000-0001-8888-3853
Markhard, Andrew L.
Zhao, Mingming
Qi, Wei
Reghupaty, Saranya C.
Zhao, Meng https://orcid.org/0000-0002-5415-8335
Spaas, Jan
Wei, Wei https://orcid.org/0000-0001-8110-0705
Moholdt, Trine https://orcid.org/0000-0003-1024-8088
Hawley, John A. https://orcid.org/0000-0002-0886-9881
Voldstedlund, Christian T. https://orcid.org/0000-0002-6368-8995
Richter, Erik A. https://orcid.org/0000-0002-6850-3056
Chen, Xiaoke https://orcid.org/0000-0001-9032-9093
Svensson, Katrin J. https://orcid.org/0000-0001-5376-5128
Bernstein, Daniel https://orcid.org/0000-0001-7761-5853
Leinwand, Leslie A. https://orcid.org/0000-0003-1470-4810
Xu, Yong https://orcid.org/0000-0002-4908-1572
Long, Jonathan Z. https://orcid.org/0000-0003-2631-7463
Funding for this research was provided by:
U.S. Department of Health Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK124265)
U.S. Department of Health Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (K99DK141966)
Article History
Received: 5 June 2025
Accepted: 10 February 2026
First Online: 19 March 2026
Competing interests
: A provisional patent application has been filed by Stanford University on para -tyramine-O-sulphate for the treatment of cardiometabolic diseases. J.Z.L. and S.X. are listed inventors. J.Z.L. and K.J.S. are cofounders, equity holders and advisers to Merrifield Therapeutics. J.Z.L. is a cofounder, equity holder and adviser to Arkana Therapeutics and an adviser to Metabolize Inc. The other authors declare no competing interests.